Oct 31, 2016 12:03 pm UTC| Business
CORAL GABLES, Fla., Oct. 31, 2016 -- Catalyst Pharmaceuticals, Inc.(Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating...
Heron Announces September 2016 Quarterly Update on the High Grade Woodlawn Zinc-Copper Project
Oct 31, 2016 12:01 pm UTC| Business
Sydney, Australia, Oct. 31, 2016 -- Heron Resources Limited (TSX: HER; ASX: HRR) ("Heron" or the "Company") announces its quarterly activities for the three months ended September 30, 2016. Details of the Company's...
Heron Announces September 2016 Quarterly Update on the High Grade Woodlawn Zinc-Copper Project
Oct 31, 2016 12:01 pm UTC| Business
Sydney, Australia, Oct. 31, 2016 -- Heron Resources Limited (TSX: HER; ASX: HRR) ("Heron" or the "Company") announces its quarterly activities for the three months ended September 30, 2016. Details of the Company's...
MyoKardia to Present at Two Upcoming Investor Conferences in November
Oct 31, 2016 12:01 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2016 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases,...
MyoKardia to Present at Two Upcoming Investor Conferences in November
Oct 31, 2016 12:01 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2016 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases,...
FibroGen Completes Enrollment in Roxadustat Phase 3 Studies in China
Oct 31, 2016 12:01 pm UTC| Business
SAN FRANCISCO, Oct. 31, 2016 -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company, today reported completion of enrollment in its Phase 3 clinical trials in China for roxadustat (FG-4592) in...
FibroGen Completes Enrollment in Roxadustat Phase 3 Studies in China
Oct 31, 2016 12:01 pm UTC| Business
SAN FRANCISCO, Oct. 31, 2016 -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company, today reported completion of enrollment in its Phase 3 clinical trials in China for roxadustat (FG-4592) in...